Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.
